Abstract 15849: Impacts of Coexistence of Metabolic Syndrome and Chronic Kidney Disease on Serum Heart-Type Fatty Acid-Binding Protein Levels in General Population
Serum heart-type fatty acid-binding protein (H-FABP) has been widely used as a marker of ongoing myocardial damage. Recent reports showed additive interaction of metabolic syndrome (MetS) and chronic kidney disease (CKD) on risk of cardiovascular disease. The aim of this cross-sectional study was to examine the impacts of coexistence of MetS and CKD on serum H-FABP levels in community-dwelling residents.We measured serum H-FABP levels in 3510 individuals > 40 years old in Takahata, Japan (men 1575, women 1935, mean 63 ± 10.4 years). MetS was defined according to American heart association (AHA) scientific statement 2009. CKD was defined as decreased estimated glomerular filtration rate (eGFR) (< 60 ml/min/1.73m̂2). There were 240 subjects with CKD and 735 subjects with Mets. The subjects with CKD were older, and had higher body mass index, higher systolic blood pressure, higher triglyceridemia, and lower high density lipoprotein cholesterol compared with those without CKD. There were no differences in low density lipoprotein cholesterol. The subjects with CKD had a higher prevalence of MetS compared with those without CKD (33.8% vs. 19.9%, p 4.3 mg/dl) in subjects with both CKD and MetS was 9.23 compared with those without CKD and MetS (95% confidence interval [CI], 4.93 to 17.3) (Figure2). In Conclusions, this study suggested that CKD and MetS often occur together, and additive disease interaction may augment risk of cardiovascular disease.
- © 2010 by American Heart Association, Inc.